Discover the first predictive clinical decision support tool
PredictionStar is an innovative aid for Breast Cancer physicians and patients, deserving optimal therapy.
Tumor typing has never facilitated optimal treatment with predictable outcomes – until now.
Empowering optimal therapies with
predictable outcomes – every patient!
All of this, highly cost-effectively and neutral for health care budgets.
OncoGenomX provides the first cancer profiling technology reflective of biology, clinical behavior, and pharmacological vulnerabilities of individual cancers to guide decisions on the composition of therapy regimen, combining the most effective drugs with the highest chance of conveying maximum clinical and health economic benefit.
We envision a future of precision cancer tests, enabling perfect matching of therapies and tumors, comprehensive, accurate, predictive, and actionable. Only therapy that hits a tumor’s biological weak points eliminates cancer effectively as a basis for prolonged life expectancy, if not curing it.
The current risk-adopted Breast Cancer therapy approach – intensive therapy for high-risk, moderate therapy for low-risk patients – is all but optimal and has a variety of undesirable consequences, most importantly suboptimal therapy outcomes. According to recent estimates, half of the women in Europe and the US diagnosed with Breast Cancer (750.000 every year) run the risk of under- or over-treatment.
We know, accounting for the properties of individual cancers makes a difference to patients.
For this reason we have developed PredictionStar.
PredictionStar is the first of its kind point-of-care technology platform, amenable to any molecular cancer diagnostics laboratory.
The technology works by using patented algorithms for analysis of tumor-specific genomic, biological, pathological, and patient-specific clinical information, complemented by intelligence-augmented drug – tumor matching, calibration with real-world outcome data to guide evidence-based therapy decisions.
Current prognosis and mutation-centrism makes PredictionStar a must-have Breast Cancer diagnostic.
We have just completed the analysis of 1’100 METABRIC study patients of the 2’400 total Breast Cancers we have studied, and a cost-effectiveness study with the renowned IFEG institute, confirming the potential of a 2-fold improved prescription precision, a 3-fold risk reduction of under- or overtreatment, a 3-fold improved chance of durable clinical benefit, and a 2-fold reduction of targeted therapy expenses [OGX-Study 2106-01 (Final study report on file)].
Cancer profiling with PredictionStar encompasses measurement of gene expression patterns and detection of molecular aberrations in archival formalin-fixed, paraffin-embedded, and eosin-stained (FFPE) tumor tissue, and molecular profiling of longitudinally collected blood samples.
To maximize the clinical utility, PredictionStar offers an effortless and intuitive feedback routine powered by advanced machine learning for continuous improvement of test results and increasing numbers of patients benefitting from PredictionStar use.
Our leadership team
We have assembled a team of 5 accomplished industry pioneers with complementary expertise, including company-building, diagnostics platform-building, and molecular cancer diagnostics. We are united by the passion of making PredictionStar a diagnostic routine for all Breast Cancer patients, as the steppingstone to biology- and clinical evidence-guided cancer therapy.
Our Chief Technology Officer and Chief Diagnostics Officer will join after successful series A investment.